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In this month’s journal club we explore the significance of 
seizures in patients with dementia, events that can be dis-
tressing for both patients and relatives. Unprovoked sei-
zures in Alzheimer’s disease are thought to affect up to a 
fifth of patients. However, seizures may be more difficult to 
identify so that rather than classical motor manifestations, 
patients may exhibit episodic confusion, behavioural change, 
increased drowsiness and/or clumsiness. The post-ictal state 
can also manifest as prolonged episodes of altered mental 
state which may further obscure or delay the diagnostic pro-
cess leading to misdiagnoses with psychiatric disorders, met-
abolic disorders or transient ischaemic attacks. In addition, 
the effects of recurrent seizure activity on cognitive decline 
in these patients remain unclear. The first paper discussed 
looks at a novel way to investigate patients with Alzheimer’s 
disease and suspected seizure activity. In the second paper, 
Vossel et al. explore the impact of subclinical epileptiform 
activity and its effects on cognition. Finally, the third paper 
discussed investigates the pathological mechanism of cogni-
tive impairment in temporal lobe epilepsy specifically con-
sidering whether the presence of a tauopathy in temporal 
lobe resections links epilepsy to the pathology underlying 
Alzheimer’s disease and chronic traumatic encephalopathy.
Silent hippocampal seizures and spikes 
identified by foramen ovale electrodes 
in Alzheimer’s disease
Hypometabolism and cellular neurodegeneration in the tem-
poral lobe are common features of both Alzheimer’s disease 
and epilepsy. Lam et al. hypothesise that intermittent tempo-
ral lobe dysrhythmia could account for the early fluctuations 
in cognition in patients with Alzheimer’s disease. In this 
paper, the authors report two cases of Alzheimer’s disease in 
which there was a high index of suspicion for occult seizure 
activity with no history of clinical seizures or epilepsy. Both 
patients were initially investigated with video EEG, which 
revealed infrequent epileptiform activity that was more prev-
alent during sleep. However, when bilateral foramen ovale 
electrodes were inserted, more frequent spike-and-wave 
activity was recorded arising from the mesial temporal lobe. 
In the first case, episodic confusion had led to a suspicion 
of subclinical seizure activity without scalp EEG evidence. 
With foramen ovale electrode placement, there was evidence 
of epileptiform activity whilst the patient was sleeping not 
present on the simultaneous scalp EEG. Levetiracetam was 
then introduced with the foramen ovale electrodes still in 
place subsequently revealing greatly reduced epileptiform 
activity and substantial clinical improvement. Similarly, 
foramen ovale insertion in the second patient resulted in the 
identification of a higher degree of subclinical seizure activ-
ity compared to scalp EEG. However, the second patient was 
unable to tolerate anti-epileptic therapy.
Comment
The authors present a novel way to successfully determine 
whether patients with Alzheimer’s disease are having sub-
clinical seizures where standard EEG has been insufficient 
for diagnosis. The bilateral foramen ovale electrodes are 
described as minimally invasive, however, they do require 
general anaesthesia for insertion as well as prophylactic anti-
biotics whilst in situ. The study is clearly limited by its small 
sample size and a larger sample size would be needed to val-
idate the findings, but it may be difficult to identify patients 
as a result of potential ethical problems. In contrast, it could 
be argued that in the context of a substantial suspicion of 
seizure activity, a trial of anti-epileptic medication would be 
warranted and the first patient’s response to Levetiracetam 
was clearly encouraging. There is currently no single anti-
epileptic drug of choice for seizures in Alzheimer’s disease 
which would also require large-scale studies to support an 
effective, evidence-based therapy.
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Incidence and impact of subclinical 
epileptiform activity in Alzheimer’s disease
Seizure activity is more common in dementia than in the 
general population and is associated with greater clinical 
decline. Understandably concern is raised when patients 
demonstrate clinically identifiable seizures but the impact 
of subclinical seizures is less clear. Vossel et al. hypothesise 
that subclinical epileptiform activity is more prevalent in 
Alzheimer’s disease than healthy controls and is associated 
with more rapid cognitive decline. As a standard 30-min 
scalp electroencephalography may be insufficient to detect 
subclinical seizures, participants underwent extended video 
EEG followed by magnetoencephalography (MEG). 33 indi-
viduals with Alzheimer’s disease were recruited. 42% had 
evidence of subclinical epileptiform activity compared to 
10.5% of the 19 age-matched controls. Epileptiform activity 
was most often detected from the temporal lobe and more 
frequently seen during deeper stages of sleep. No subclinical 
seizures were recorded during the monitoring. The partici-
pants with Alzheimer’s disease and evidence of epileptiform 
activity tended to be younger but the link was not significant. 
On longitudinal evaluation, those individuals with subclini-
cal epileptiform activity were significantly associated with 
an increased cognitive decline over 5 years measured with 
serial mini-mental state examination (MMSE) assessments.
Comment
This study reveals a significant proportion of patients with 
Alzheimer’s disease that demonstrate subclinical epilepti-
form activity on extended monitoring. This is in keeping 
with the hypothesis that subclinical seizure activity in Alz-
heimer’s disease is currently under-estimated. The clinical 
significance of these findings is highlighted by the longitu-
dinal data which shows an association between epileptiform 
activity and cognitive decline. However, there is not enough 
evidence from this study to establish a causal relationship. It 
could be argued that subclinical epileptiform activity may be 
a result of a more aggressive disease course. Further analysis 
of the relationship between seizure activity and cognitive 
decline in Alzheimer’s disease is required. As expected, 
extended EEG-monitoring and the combination of MEG 
and EEG was more sensitive in detecting subclinical epi-
leptiform activity than standard scalp EEG. However, the 
relevance of this in a clinical setting depends on whether 
anti-epileptic medication is of benefit to these patients—an 
area which certainly warrants further exploration.
Vossel KA et  al. (2016) Annals of Neurology. 80: 
858–870.
Hyperphosphorylated tau in patients 
with refractory epilepsy correlates 
with cognitive decline: a study of temporal 
lobe resections
The pathological features of Alzheimer’s disease, including 
amyloid plaques and neurofibrillary tangles consisting of 
hyperphosphorylated tau, are well described. The pathology 
underlying the cognitive decline seen in temporal lobe epi-
lepsy (TLE) is less well understood. In a clinicopathological 
study, the authors of this paper investigate the relationship 
between TLE and tau pathology. The tissue from temporal 
lobe resections performed in patients with chronic refractory 
TLE was examined to assess the presence and extent of tau 
pathology using a modified tau score. Post-operative cogni-
tive scores were then compared to the extent of tau pathol-
ogy. The patients with higher tau scores were significantly 
associated with greater post-operative decline in verbal 
learning and recall. There was also a significant association 
between a history of secondary generalised seizures and a 
higher tau burden. With the majority of samples showing 
hippocampal sparing as well as an absence of beta-amyloid 
plaques, the pathology was not thought to be typical of that 
seen in Alzheimer’s disease. It was also not consistent with 
the classical findings of chronic traumatic encephalopathy. 
The authors suggest an epilepsy-specific tauopathy could 
underlie the cognitive decline in TLE and state that this war-
rants further investigation.
Comment
This study offers an interesting insight into the pathology 
of patients with TLE with further evaluation of their cogni-
tive function post-resection, setting this study apart from 
previous post-mortem studies. The tau burden observed was 
not significantly higher than in a post-mortem study of the 
general population which raises the possibility that hyper-
phosphorylated tau may not be the only factor contribut-
ing to cognitive decline in epilepsy. There appears to be 
significant association between generalised seizures, extent 
of tau pathology and cognitive decline but it is difficult to 
be certain of the causative relationship linking these fea-
tures from this study alone. Although there were differences 
seen in terms of the pattern of pathology when compared 
to the primary age-related tauopathies, the study supports 
the idea that epilepsy has an integral neurodegenerative ele-
ment. These findings and related studies will be of benefit to 
future therapies that target neurodegenerative changes and 
tau pathology.
Tai XY et al. (2016) Brain. 139: 2441–2455.
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